
usd jul pm et
summari maker radiotherapi cancer system also suppli x-ray tube flat-panel digit
subsystem imag medic scientif industri applic
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
apr stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra keep sell
system inc lower
target price reflect multipl
ep near
averag jun-q ep
consensu expect yet
narrow full-year ep guidanc
point higher interest expens
invest sg spend
cost driver lower fy sep ep
fy ep
constant currenc million oncolog
order grew constant currenc
order america decreas emea
increas apac decreas despit
soft across apac china double-digit
neg impact earn million
quarter despit receiv three new order
proton solut segment total
charg proton busi reflect
larg establish custom base
equip servic high switch cost
addit compani typic maintain net
cash posit gener posit free cash flow
hand industri cancer treatment
highli competit character technolog
innov new product entrant although radiat
therapi like continu integr compon
global cancer treatment protocol continu
develop drug-bas oncolog treatment
repres substanti threat compani
fiscal year end sep ep estim base cfra
oper earn histor earn report
cash dividend paid last year
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview varian world lead manufactur medic devic softwar
treat cancer medic condit radiotherapi stereotact radiosurgeri
stereotact bodi radiotherapi brachytherapi proton therapi oper group two
report oper segment oncolog system varian particl therapi vpt oncolog system
repres bulk revenu segment made total revenu
fiscal year sep respect
market profil driven age global popul improv diagnost method number
newli diagnos cancer case continu increas number new cancer case diagnos annual
project increas million million accord
intern agenc research cancer world organ
radiat therapi commonli use treatment cancer alon combin surgeri
chemotherapi common type radiotherapi use x-ray deliv extern beam
administ use linear acceler addit extern radiat radioact seed wire ribbon
sometim insert tumor bodi caviti brachytherapi modal
requir radiat pass healthi tissu
varian oncolog system busi design manufactur sell servic hardwar softwar
product treat cancer convent radiotherapi advanc treatment fix field
sbrt brachytherapi
vpt busi develop design manufactur sell servic product system deliv
proton therapi anoth form extern beam radiotherapi use proton beam treatment
cancer although proton therapi clinic use four decad wide
deploy due high capit cost var current focu improv proton therapi clinic util
reduc cost treatment per patient wide accept deploy therapi
thought especi use pediatr case larg tumor ocular tumor tumor
adjac sensit healthi tissu
major develop major develop fiscal far
attempt acquir sirtex medic limit manufactur target radioact treatment liver
cancer billion howev sirtex receiv stronger counteroff outbid
quarter end decemb divest former imag compon busi
corpor quarter also absorb ginzton technolog center busi previous
reflect oncolog system busi
competit landscap market radiat therapi equip softwar character
rapidly-evolv technolog intens competit price pressur view radiotherapi
radiosurgeri market primarili compet elekta ab accuray incorpor
inform imag manag simul treatment plan radiosurgeri product
compet varieti compani philip medic system raysearch laboratori ab
brainlab ag best theratron ltd
addit substanti amount resourc invest research develop new
therapi cancer success develop altern therapi cancer
immunotherapi increas efficaci new therapi exist product price decis
competitor rate market penetr competit product may render var product
obsolet noncompetit
financi trend fy sep revenu grew billion billion
adjust ep fy repres increas prior year five-year
compound annual growth rate compound-annual-growth-rate adjust ep fy approxim zero recent year
compani tend maintain net cash posit posit free cash flow defin cash flow
oper less capit expenditur
senior vice presid
senior vice-president financ
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
bullish sinc june technic indic
bullish
figur base fiscal year-end price
growth rate averag
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
neutral continu expect compani
sub-industri achiev robust organ
growth posit macroeconom environ
compani gener benefit new
product launch laxer food drug
administr fda technolog advanc
sub-industri also mani product area
histor recession-resist
equip use non-elect procedur
howev valuat health care equip
compani elev rel
composit suggest posit
fundament reflect share
think higher valuat
sub-industri mostli warrant
strong recent margin expans revenu
growth associ robust product
expect sub-industri earn rise
high-single-digit percentag driven
continu pipelin innov new product
emerg market expans speed
new product come market
increas recent year
success effort fda reduc
approv time medic devic
time see price pressur incess
headwind medic equip compani
impact china-u trade war appear
insignific far medic
equip compani especi sinc
base medic equip manufactur
sourc insignific amount product
input china addit
chines govern seek lower health
care cost provid better health care
insul medic equip
sub-industri mount trade tension
larg medic equip target
chines tariff mean certain
compani
like
hurt trade tension howev bigger
concern medic equip
manufactur potenti trade
tension caus signific slowdown
possibl threat state american
health care system lawsuit texa
rule unconstitut
current expect upheld upon
appeal although decis could take
coupl year reach democrat
took control hous repres
period think
see substanti effort
republican trump administr
tri repeal
anoth legisl issu could impact
medic equip manufactur
potenti return medic devic tax
medic devic tax suspend
end congress fail
repeal suspend tax medic
devic manufactur could significantli
gener see posit long-term
fundament includ increas global
demand cost-effect value-bas
health care age popul rise
outlay result steadi flow
innov product revenu growth
year-to-d june
vs increas valu
 composit index
vs declin composit
base index
five-year market price perform jul
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra keep hold opinion share varian medic
system inc lower target
in-lin peer ep estim multipl
near middl var five-year rang sep-q ep vs
lower estim lower fy sep ep
initi fy ep estim sep-q sale increas
constant currenc million driven growth
oncolog system segment emea region perform strongli
sep-q revenu grew year-over-year america grew
apac region grew oncolog revenu neg impact chines
retaliatori tariff enact august implement action suppli
chain commerci oper mitig impact tariff
proton beam busi book new probeam order anoth
et cfra upgrad opinion share varian medic system
hold sell maintain twelve-month target
next-twelve-month ep estim multipl
near middl var five-year rang sell
rate base primarili valuat see compani current
trade near target price lift opinion share
hold continu expect intern order account
futur order focus much effort expand
presenc establish intern market emerg market
think compani halcyon radiotherapi machin probeam proton
therapi could long-term growth driver although remain cautiou
var abil meaning expand market addit sale
probeam histor lumpi /kevin huang cfa
analyst research note compani news
et cfra keep sell opinion share varian medic system
inc lower target price reflect
multipl ep near averag
jun-q ep vs significantli exceed consensu
expect yet narrow full-year ep guidanc
point higher interest expens invest sg spend
cost driver lower fy sep ep
fy ep jun-q sale increas constant
currenc million oncolog order grew constant currenc
order america decreas emea increas apac decreas
despit soft across apac china double-digit unspecifi growth
us-china tariff neg impact earn million quarter
despit receiv three new order proton solut segment total
million took million impair charg proton busi
et cfra reiter sell opinion share varian medic
system inc lower target reflect
multipl ep near averag
mar-q ep vs lower estim
stronger-than-expect impact tariff addit
increas project cost site delay proton solut busi
lower sep ep maintain ep
mar-q sale increas constant currenc million oncolog
order constant currenc order america increas
emea apac sale apac region driven
acceler growth china despit manag revenu guidanc
rais think revenu growth could pressur
unfavor work capit trend mar-q receiv day dso
increas year-over-year defer revenu day dsdr decreas
trend hint possibl slowdown /kevin huang cfa
et cfra lower opinion share varian medic system inc
sell hold share risen year-to-d
push beyond price target valuat repres forward
price-to-earnings ratio forward earn estim ratio high-end
three-year forward price-to-earnings rang like buoy
recent optim expect roughli half futur revenu growth
tie market outsid market could pressur
gener slow global econom activ believ share
trade fair valu especi given recent deterior work
receiv depress current defer revenu well chines tariff
concern process request grant tariff
exclus china lower price target
reflect forward price-to-earnings multipl three-year averag
et cfra maintain hold opinion share varian medic
system inc rais target
ep estim multipl toward
high-end five-year rang see gain momentum
china dec-q ep vs lower estim
rais sep ep ep
dec-q sale increas constant currenc million
oncolog order dec-q million order
america increas emea apac driven acceler growth
china recent enact tariff china neg
impact revenu million oper earn million
dec-q manag cautious optimist china might provid
tariff relief halcyon system also expect see
tariff mitig action carri second half fiscal
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
